Related Experiment Videos
Moricizine: a novel antiarrhythmic agent
1College of Pharmacy, Ohio State University, Columbus 43210.
DICP : the Annals of Pharmacotherapy
|July 1, 1990
Summary
Moricizine, a class 1 antiarrhythmic drug, shows comparable efficacy to other agents in treating ventricular arrhythmias but with fewer serious adverse effects. Further research is recommended for life-threatening arrhythmias.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Medicine
Background:
- Moricizine is a phenothiazine derivative with Vaughan Williams class 1 antiarrhythmic properties.
- It exhibits extensive first-pass metabolism, with 34-38% bioavailability and 95% plasma protein binding.
- Moricizine is extensively metabolized, potentially yielding active metabolites.
Purpose of the Study:
- To evaluate the efficacy and safety of moricizine compared to other antiarrhythmic agents.
- To assess its role in treating ventricular arrhythmias, including premature depolarizations, couplets, and ventricular tachycardia.
Main Methods:
- Clinical study comparing moricizine with encainide, flecainide, disopyramide, and quinidine.
- Assessment of suppression of ventricular premature depolarizations, couplets, and nonsustained ventricular tachycardia.
Main Results:
- Moricizine was slightly less effective than encainide or flecainide for ventricular premature depolarizations.
- It demonstrated equal or greater efficacy than disopyramide and quinidine for ventricular arrhythmias.
- Moricizine appears to have a low incidence of serious adverse effects compared to other antiarrhythmics.
Conclusions:
- Moricizine shows comparable efficacy to other class 1 agents in treating ventricular tachycardias and fibrillation.
- Its favorable safety profile suggests it is a valuable addition to antiarrhythmic therapy.
- Further comparative studies are warranted for life-threatening arrhythmias.